USG Proceedings Journal

Meeting Report

Open Access

Report on the 3rd Global Cell & Gene Therapy (CGT) Summit 2026

Nidhi Kotecha*

Regulatory Affairs, Gates Institute, Colorado, United States

***Correspondence to:**
Nidhi Kotecha
Regulatory Affairs,
Gates Institute,
Colorado, United States.
E-mail: nidhi.kotecha@cuanschutz.edu

Received: July 11, 2026
Accepted: July 20, 2026
Published: July 24, 2026

Citation: Kotecha N. 2026. Report on the 3rd Global Cell & Gene Therapy (CGT) Summit 2026. *USG Proc J* 2(1): 2.

Copyright: © 2026. Kotecha. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY) (http://creativecommons.org/licenses/by/4.0/) which permits commercial use, including reproduction, adaptation, and distribution of the article provided the original author and source are credited.

Published by USG United Scientific Group

Meeting Report

The 3rd Global Cell & Gene Therapy (CGT) Summit 2026 successfully brought together a distinguished community of scientists, clinicians, biotechnology and pharmaceutical leaders, investors, regulatory experts, and innovators to discuss the latest advancements and future directions in cell and gene therapy.

The summit served as a collaborative platform for knowledge exchange, scientific discussion, and partnership development, featuring an engaging program of keynote lectures, technical presentations, panel discussions, and networking opportunities. Participants explored emerging trends in gene editing, stem cell therapies, immunotherapy, regenerative medicine, manufacturing innovations, commercialization strategies, regulatory developments, and investment opportunities shaping the future of advanced therapeutics. The conference highlights are as follows:

- International participation from academia, industry, clinical research, and regulatory organizations.
- Inspiring keynote presentations delivered by globally recognized leaders in cell and gene therapy.
- Scientific sessions showcasing cutting-edge research, translational medi cine, and commercial advancements.
- Interactive panel discussions addressing manufacturing, regulatory path ways, market access, and future innovations.
- Dedicated networking sessions that fostered new collaborations between researchers, clinicians, biotechnology companies, investors, and solution providers.

CGT Summit 2026 strengthened collaborations across the global cell and gene therapy community while providing attendees with valuable insights into scientific breakthroughs, clinical applications, manufacturing technologies, and commercialization strategies. The discussions highlighted the importance of multidisciplinary collaboration in accelerating the development and accessibility of next-generation therapies for patients worldwide.

Building on the success of the 2026 edition, the 4th Cell & Gene Therapy (CGT) Summit 2027 will continue to expand its global scientific network and provide an even broader platform for innovation, collaboration, and knowledge sharing. We look forward to welcoming the international community once again to explore the next generation of transformative cell and gene therapies.

We extend our sincere appreciation to all speakers, session chairs, delegates, sponsors, exhibitors, and organizing committee members whose valuable contributions made the Cell & Gene Therapy Summit 2026 a great success. Their expertise, engagement, and support were instrumental in creating a meaningful and impactful scientific event.